account_id none on file
legal_name Travere Therapeutics, Inc.
ticker TVTX
cik 1438533
domain travere.com
linkedin_company_url https://www.linkedin.com/company/travererare
entry_point_account_id none on file
name Travere Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq San Diego, CA, United States
sector index/company/sector/health-care/
calls 1 filings 3 executives 8 family 0
why_nownone on file
calls
With our current strong cash balance, expected significant growth in Tospari, continued expense management, and anticipated incoming future milestone payments, we continue to expect that our balance sheet can support current operations into 2028.
May 6, 2024 / receipt, needs a key / Chris Klein, CFO | earnings call 2024-05-06 | transcript 1473915c-0d6a-473c-892b-84d7e7cc349e | chars 21551-21797 | segment 21
filings
An established nephrology team of 100+ field professionals
ir_statement / Sep 15, 2026 / receipt
Estimated >$3B potential peak opportunity for FILSPARI in the U.S.
ir_statement / Sep 15, 2026 / receipt
Execute a successful launch in FSGS by leveraging IgAN commercial success and infrastructure.
ir_statement / Sep 15, 2026 / receipt
executives
| Chris Klein | CFO | - | receipt |
| Eric Dube | CEO | - | receipt |
| John A. Orwin | director | - | receipt |
| Jule Enrig | CMO | - | receipt |
| Peter Herma | Chief Commercial Officer | - | receipt |
| Ron Squarer | director | - | receipt |
| Ruth Williams-Brinkley | director | - | receipt |
| Sandra Poole | director | - | receipt |
familynone on file
upcoming
changes
| 2021-09-14 | director, appointed | sec_8k |
| 2019-09-18 | director, appointed | sec_8k |
| 2017-05-19 | director, appointed | sec_8k |
| 2017-05-19 | director, appointed | sec_8k |
| 2017-04-13 | director, appointed | sec_8k |
| 2017-03-27 | director, appointed | sec_8k |
mcp_package_hint
slug travere-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$